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Abstract
Multiple system atrophy (MSA) is a rare, yet rapidly-progressive neurodegenerative disease that presents
clinically with autonomic failure in combination with parkinsonism or cerebellar ataxia. The definitive
neuropathology differentiating MSA from Lewy body diseases is the presence of α-synuclein aggregates in
oligodendrocytes (called glial cytoplasmic inclusion or GCI) rather than the fibrillar aggregates in neurons
(called Lewy bodies). This makes the pathological pathway(s) in MSA unique in that oligodendrocytes are
involved rather than predominantly neurons, as is most other neurodegenerative disorders. MSA is therefore
regarded as an oligodendrogliopathy. The etiology of MSA is unknown. No definitive risk factors have been
identified, although α-synuclein and other genes have been variably linked to MSA risk. Utilization of postmortem brain
tissues has greatly advanced our understanding of GCI pathology and the subsequent neurodegeneration. However,
extrapolating the early pathogenesis of MSA from such resource has been difficult and limiting. In recent years, cell and
animal models developed for MSA have been instrumental in delineating unique MSA pathological pathways, as well
as aiding in clinical phenotyping. The purpose of this review is to bring together and discuss various animal models
that have been developed for MSA and how they have advanced our understanding of MSA pathogenesis, particularly
the dynamics of α-synuclein aggregation. This review will also discuss how animal models have been used to explore
potential therapeutic avenues for MSA, and future directions of MSA modeling.
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Introduction
Multiple system atrophy is a fatal neurodegenerative dis-
ease characterized by the clinical triad of parkinsonism,
cerebellar ataxia and autonomic disturbance. The annual
incidence in the 50–99 year age group is 3 per 100,000
person years with a mean survival of 9 years from diag-
nosis [1, 2]. Underlying neuropathology is characterized
by widespread proteinaceous inclusions in oligodendro-
cytes, the myelin producing support cells of the CNS.
The glial cytoplasmic inclusions (GCIs) are accumula-
tions of α-synuclein (Fig. 1), a protein enriched in synap-
ses that also accumulates pathologically in neurons in
Parkinson’s disease (PD) and dementia with Lewy bodies
(DLB). GCIs and the resulting neurodegeneration occur
in a typical multisystem distribution encompassing the
striatonigral and olivopontocerebellar systems and auto-
nomic nuclei of the brain stem and spinal cord [3, 4].
MSA can be divided into two main subtypes, a parkin-
sonian subtype (MSA-P) with striatonigral degeneration
and a cerebellar subtype (MSA-C) with pontocerebellar
degeneration [5]. Both subtypes feature autonomic dys-
function, with associated GCIs and degeneration in a
distributed network of autonomic brain regions [5, 6].
Case series from different ethnic populations suggest a
racial variation in the prevalence of MSA subtypes. In a
UK cohort of 100 cases MSA-P predominated in 34 %
while 17 % had MSA-C and 49 % had equally distributed
pathology [6]. In contrast a Japanese cohort of 50 cases
demonstrated MSA-C subtype in 40 %, equal pathology
in 42 % and 18 % with MSA-P phenotype.
The etiology and early pathogenesis of MSA remain
enigmatic. Epidemiological studies are limited by low
case numbers and the difficulty of obtaining definitive
clinical diagnosis [7–12]. Unlike PD, no single gene mu-
tations linked to familial forms of the disease have been
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identified. Multiplex families with MSA have been re-
ported [13–15], but no common genotype has been
identified and the existence of true Mendelian forms of
the disease is questionable. Candidate gene studies have
found genetic variation in the SNCA locus associated
with a risk of MSA [16–18]. However, these are not sub-
stantiated in all cohorts [12]. Furthermore a pioneering
GWAS found no risk conferring loci on the SNCA gene
[19]. Recently, two new genes, COQ2 [20] and glucocer-
ebrosidase (GBA) [21], have been identified as risk fac-
tors for MSA. Recent transcriptomic studies of MSA
brain have provided new insights into the molecular
pathology of MSA. RNA-Seq analyses have revealed al-
terations in a number of genes in MSA brain including
alpha and beta hemoglobin (HBA1, HBA2 and HBB) and
transthyretin [22]. An analysis of microRNAs has re-
vealed a widespread dysregulation of microRNAs in
MSA brain [23]. Changes to microRNA-96 resulted in
downregulation of the solute carrier protein family
SLC1A1 and SLC6A6 [23]. Myelin instability is regarded
as an early event in MSA pathogenesis and a recent study
showed that the myelin lipids (sphingomyelin, sulfatide
and galactosylceramide) were severely decreased in MSA
white matter specifically in disease-affected regions, pro-
viding further clues to MSA pathogenesis [24, 25].
Despite the emergence of new data, in the absence of
definitive genetic leads, understanding of early patho-
genic events must be interpolated from studies of ad-
vanced cases that become available as postmortem
specimens. For all these reasons the development of cell
and animal models of MSA has been immensely import-
ant for our understanding of the disease. Unfortunately
these same knowledge gaps, particularly lack of causative
mutations, make generating valid models of MSA more
difficult. Existing models rely on phenotypic replication
of the major neuropathological feature of the disease,
namely oligodendrocyte accumulation of α-synuclein.
Nonetheless these models remain instrumental for explor-
ing (1) the dynamics of α-synuclein aggregation in cells,
(2) pathways from GCI formation to glial and neuronal
degeneration, and (3) potential targets for neuroprotective
and disease-modifying therapies. This review will describe
animal models of MSA and discuss the insights gained as
well as limitations and future directions of such research.
Review
Glial cytoplasmic inclusions
Substantial numbers of α-synuclein-positive GCIs are the
distinguishing pathological hallmark of MSA. GCIs are
typically located close to or surrounding the nucleus of ol-
igodendrocytes (Fig. 1). Filamentous aggregations of phos-
phorylated α-synuclein, similar to GCIs, are also found in
Schwann cells predominantly in the anterior nerve of the
sacral cord [26]. GCIs have varied morphology ranging
from triangular or conical to half-moon shaped [27]. Im-
munohistochemical studies have identified a growing list
of proteins colocalized with α-synuclein in GCIs including
p25α, αβ-crystallin, ubiquitin and tubulin [28]. Ultrastuc-
turally GCIs are composed of loosely packed filaments of
α-synuclein misfolded in a ß-sheet conformation [29, 30].
α-Synuclein in GCIs of MSA is phosphorylated at residue
Ser-129, as is the case in Lewy bodies of PD and DLB [31].
Phosphorylated α-synuclein is also ubiquinated [32].
α-Synuclein is a cytosolic protein that occurs pri-
marily in neurons where it has a propensity to associ-
ate with lipid membranes [33–36] and is concentrated
in synapses. Characteristic changes in the solubility of
α-synuclein are observed in homogenates of MSA-
affected tissue. In the largest multi-region examin-
ation of α-synuclein solubility in MSA brains, Tong
and colleagues [37] observed a dramatic accumulation
of membrane associated α-synuclein (sodium dodecyl
sulfate (SDS)-soluble fraction) specific to disease-
affected regions, a finding confirmed in other studies
Fig. 1 The pathological hallmark of MSA is the presence of glial
cytoplasmic inclusions (GCIs) in the brain. Micrographs show white
matter underlying the motor cortex stained using α-synuclein
immunohistochemistry and Nissl counterstaining (0.5 % cresyl violet).
The typical GCI aggregates in oligodendrocytes in MSA (also shown at
higher power in inset) are not found in healthy controls
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[38–41]. These observations suggest a solubility shift
of α-synuclein out of the cytosolic compartment may
be a key step in MSA pathogenesis.
Oligodendrocyte cell lines
Prior to developing animal models of MSA, in vitro
studies have relied on the use of existing oligodendro-
cyte cell lines. Permanent oligodendrocyte cell lines in-
clude HOG [42] and KG1c [43], derived from resected
human glioma specimens; MO3.13, adult human oligo-
dendrocytes fused with a neoplastic cell line [44]; and
OLN-93, derived from transformed rat oligodendrocytes
[45]. The protein expression profiles and morphology of
these cells bear resemblance to immature oligodendro-
cytes however some further in vitro differentiation can
be induced in HOG and MO3.13 cells in which case cell
proliferation is reduced [46]. Like primary human oligo-
dendrocytes these clonal cell lines do not express signifi-
cant levels of α-synuclein, thus genetic manipulation is
required to reproduce the features of MSA.
In an early cell-transduction study Stefanova and col-
leagues found that overexpression of α-synuclein in an
astrocytoma cell line and rat primary mixed glial culture
was sufficient to produce widespread fibrillar α-synuclein
aggregates and evidence of cellular stress and degener-
ation [47]. Kragh and colleagues generated a successful
cell model of MSA-like glial degeneration in OLN-93 cells
by co-expressing α-synuclein and the oligodendrocyte
microtubule-associated protein, p25α [48]. Cells express-
ing both proteins demonstrated α-synuclein aggregation
and mictrotubule retraction in association with activation
of the apoptotic protein caspase 3 (Fig. 2). These changes
were absent in cells expressing either of the proteins alone
or in combination with a host of control proteins includ-
ing β-synuclein, CRMP-2 and Tau40. Alternative to in
vitro transduction, primary cultures of oligodendro-
cytes and neurons can be prepared from the brains of
transgenic rodent models of MSA [49]. While, not able to
proliferate in vitro, these primary cultures provide an op-
portunity for closer examination of subcellular dynamics
of α-synuclein accumulation and cytotoxicity in fully dif-
ferentiated cells, as discussed below.
Stereotaxic models
The earliest models of MSA reproduced L-dopa-
unresponsive striatonigral degeneration (SND) through
the use of neurotoxins, locally or systemically delivered.
While of limited use in elucidating the pathogenic mech-
anisms underlying MSA, these models provided insights
into the interactions between striatal and nigral lesions
[50] and the neuropathological basis of SND symptom-
atology [50, 51]. Stereotaxic models have also been test
beds for early non-dopaminergic therapies against the
motor impairment of MSA, including embryonic neuronal
grafts [52, 53]. Nonetheless, the most recent advances in
modeling MSA have come from transgenic animal studies,
which will be discussed in detail below.
Transgenic murine models
Oligodendrocyte proteolipid protein promoter
Khale and colleagues first attempted to reproduce the
features of MSA in mice expressing human α-synuclein
(hα-syn) under an oligodendrocyte specific promoter,
proteolipid protein promoter (PLP) [41]. The resulting
transgenic mice (PLP-hα-syn) featured half-moon and
triangle shaped α-synuclein-positive inclusions in oligo-
dendrocytes similar to GCIs. These aggregates recapitu-
lated other biochemical features of authentic GCIs
including phosphorylated α-synuclein immunoreactivity
and SDS detergent-insolubility. However no obvious
demyelination or oligodendrocyte loss was observed in
the transgenic or control mice aged up to 18 months
(only cerebellar white matter tested). Similarly no neur-
onal loss or motor phenotype was discovered in mice up
to 10 months old.
Later studies of the same mouse line found subtle but
progressive motor impairment in mice after 12 months
of age [54, 55]. Stefanova and colleagues [55] observed
neuronal loss in the substantia nigra pars compacta
(SNc) and locus coeruleus in PLP-hα-syn mice correlat-
ing with a subtle motor phenotype of reduced hind limb
stride length. A more recent study [54] reported wide-
spread α-synuclein pathology with distribution analysis
revealing the highest burden in the globus pallidus.
There was also a 31.4 % reduction in dopaminergic neu-
rons in the SNc compared to non-transgenic mice. The
motor phenotype was again subtle with progressive im-
pairment in only one out of three tests.
The PLP-hα-syn mouse line has also shown some util-
ity in replicating non-motor aspects of the MSA pheno-
type. Stemberger and colleagues [56] reported evidence
of neurodegeneration in regions of the PLP-hα-syn
mouse brain associated with autonomic failure and other
non-motor symptoms, including the nucleus ambiguus
in the brainstem and Onufs nucleus in the spinal cord.
Kuzdas and colleagues [57] also observed neurodegener-
ation in the nucleus ambiguus and corresponding dis-
crepancies in cardiac autonomic function compared to
non-transgenic mice. Another study reported abnormal
urodynamic studies and structural changes in the bladders
of PLP-hα-syn mice suggestive of bladder dysfunction.
This corresponded to neurodegeneration observed in mic-
turition centers in the spinal cord and brainstem [58].
Oligodendrocyte myelin basic protein promoter
Shults et al. [59] produced a transgenic mouse line
expressing α-synuclein in oligodendrocytes under the
myelin basic protein promoter (MBP-hα-syn mice). Four
Bleasel et al. Acta Neuropathologica Communications  (2016) 4:12 Page 3 of 15
lines were generated with varying levels of α-synuclein
expression. Perinuclear α-synuclein inclusions with a
fibrillar structure under electron microscopy were ob-
served in oligodendrocytes. α-Synuclein in inclusions
was hyperphosphorylated and ubiquitinated. The most
extensive pathology was observed in regions commonly
affected in MSA: the basal ganglia and cerebellum.
MBP-hα-syn mice demonstrated loss of myelin staining
and astrogliosis in white matter tracts. Ultrastuctural
examination of affected oligodendrocytes revealed prom-
inent mitochondrial abnormalities including enlarged
and irregularly shaped organelles (Fig. 2). There were
Fig. 2 Insights into MSA pathophysiology. The sequence of pathological events of MSA is now recognized as abnormal protein aggregations
(GCIs) in oligodendrocytes first, followed by demyelination and then neurodegeneration and loss of neurons. GCIs are predominantly composed
of α-synuclein. Early features of MSA pathogenesis include decline in glial neurotrophic factors, mictrotubule disruption, and activation of caspase
3 and microglial toll-like receptor 4 (TLR4). Late features of MSA pathogenesis include accumulation of lysosomes and cytoplasmic myelin fragments in
oligodendrocytes, increased production of cytokines from activated microglia, and astrogliosis
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also extensive axonal alterations including decreased
fiber density and irregular swelling of axons (Fig. 2).
Dopaminergic neuronal loss in the SNc was demon-
strated. The severity of both the GCI-like pathology and
neurodegeneration positively correlated with level of α-
synuclein expression between the different MBP-hα-syn
lines. Motor phenotype severity also varied dramatically
from severe tremor, ataxia, seizures and premature death
in the highest expressing line to mild tremor and vari-
able motor impairment in intermediate and lower ex-
pressing lines. Ubhi and colleagues reported olfactory
deficits in MBP-hα-syn mice compared to non-
transgenic controls using a buried pellet finding test.
However, in contrast to PD, significant olfactory disturb-
ance is not a consistent feature of MSA [60, 61].
2’,3’-cyclic nucleotide 3’-phosphodiesterase promoter
The third MSA mouse model features expression of
human α-synuclein under the 2’,3’-cyclic nucleotide 3’-
phosphodiesterase promoter (CNP-hα-syn). Yazawa and
colleagues [62] demonstrated age-related progressive
motor deficits in CNP-hα-syn mice compared to age
matched control oligodendrocytes. GCI-like α-synuclein
inclusions and neurodegeneration were observed, most
prominently in the cerebral cortex and spinal cord.
There was a lack of overt degeneration observed in the
cerebellum and pontine nuclei, associated with a lower
level of α-synuclein expression in these regions. α-
Synuclein solubility shifts were examined with serial
extractions of homogenates from the spinal cord,
cerebrum, cerebellum and brain stem. The pattern of
high molecular weight insoluble α-synuclein in CNP-
hα-syn mice was similar to analogous extractions
from MSA tissue.
Ultrastructural examination of samples of cerebellum,
pons, cerebrum and spinal cord was undertaken with
immunocytochemistry assessed using transmission elec-
tromicroscopy. Oligodendrocytes from CNP-hα-syn mice
demonstrated degraded myelin, extensive accumulation of
lysosomes and cytoplasmic myelin fragments (Fig. 2), sug-
gesting autophagocytosis of myelin. This was associated
with α-synuclein positive filamentous inclusions in oligo-
dendrocytes and accumulation of α-synuclein within
the degenerating myelin sheath. Surprisingly while
neuronal cell bodies were not immunostained for
human α-synuclein in CNP-hα-syn mice, an antibody
that recognizes endogenous mouse α-synuclein detected
α-synuclein fibrils in a large number of axons in the spinal
cord. Very little α-synuclein immunoreactivity was ob-
served in axons of the spinal cord of control mice. This
suggests that in this MSA model, α-synuclein-induced
oligodendrocyte degeneration promotes accumulation of
endogenous mouse α-synuclein in degenerating axons. α-
Synuclein positive neuronal inclusions are a consistent
feature of MSA histopathology, though their place in the
pathogenic sequence has remained enigmatic [63]. A
recent study highlighted the neuronal accumulation of α-
synuclein in MSA [64], although the distribution and
variety of such inclusions were not observed using previ-
ous silver stains [65] and do not associate with the pattern
of neuronal loss observed, suggesting such α-synuclein
accumulations are not of the same toxic conformation as
those found in GCIs [66].
Determining the pathogenesis of MSA
The recapitulation of GCI-like inclusions in animal and
cell models of MSA offers a valuable opportunity to
study the late intracellular pathological events, including
the dynamics of α-synuclein aggregation, determinants
of α-synuclein-mediated toxicity and mechanisms of
secondary neurodegeneration (Fig. 2).
α-Synuclein interaction with microtubules
The association of α-synuclein with microtubule re-
lated proteins is of great interest to the physiological
and pathological functions of the protein (Fig. 2). In
cultured neurons, α-synuclein appears to regulate the
expression and localization of norepinephrine trans-
porter in a manner dependent on interaction with the
microtubule cytoskeleton (treatment with depolymer-
izing agent nocodazole abolished regulatory activity)
[67]. Furthermore, microtubule-dependent trafficking
was impaired in cells overexpressing α-synuclein [68].
A number of microtubule-interacting proteins have
been implicated in α-synuclein aggregation or are
found colocalized with α-synuclein in pathological ag-
gregates in both MSA and PD, including tubulin [69],
p25α [70] and tau [71].
In the OLN-93 model of MSA generated by Kragh and
colleagues [48], MSA-like glial degeneration was induced
specifically by co-expression of α-synuclein with p25α, an
oligodendrocyte protein involved in basic microtubule
assembly and myelination [72, 73]. Varying the levels of α-
synuclein expression further showed that there was a low
threshold for cytotoxicity when p25α was present. Apart
from being colocalized with α-synuclein in GCIs, p25α
promotes the fibrilization of α-synuclein in vitro [70].
Moreover, Song and colleagues [74] observed relocaliza-
tion of p25α from the myelin sheath to the swollen cell
soma in MSA oligodendrocytes before the appearance of
α-synuclein in GCIs. A recent study showed that p25α
was relocated from the nucleus to the perinuclear cyto-
plasm in the oligodendrocytes of sporadic and COQ2
MSA [75]. These results and evidence from the cell model
support the notion that microtubule disruption, possibly
linked to dysfunctional myelination, is a fundamental
event in MSA pathogenesis.
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In degenerating neurons from the CNP-hα-syn mouse,
a neuronal microtubule element, β-III tubulin, was ob-
served to be colocalized with endogenous α-synuclein
aggregates [49]. A more recent study [76] further exam-
ined the role of β-III tubulin association in the secondary
neuronal pathology using the same model of CNP-hα-syn
oligodendrocyte/neuron primary cultures. The micro-
tubule depolymerizing agent nocodazole significantly re-
duced α-synuclein aggregation in the transgenic cells
while rifampicin, a putative inhibitor of α-synuclein self-
association, had no effect. This suggests that in this
instance, association of α-synuclein with microtubule
components may be even more important than self-
association of the protein in its pathological aggregation.
Ito and colleges [77] studied the electrophysiological con-
sequences of endogenous α-synuclein accumulation in
neurons in the brains of CNP-hα-syn mice. Miniature
excitatory and inhibitory post-synaptic currents (mEPSC/
mIPSC) were measured in freshly dissected mouse brain
tissue; results showed a significant decrease in mIPSC in
transgenic mice compared to control. Again, treatment
with microtubule depolymerizing agent nocodazole res-
cued GABAergic dysfunction.
In summary α-synuclein function and pathology is
closely connected with the microtubule system in both
oligodendrocytes and neurons (Fig. 2). Further under-
standing of these associations may elucidate the early
pathogenic events occurring in oligodendrocytes prior to
GCI formation as well as providing potential therapeutic
targets to ameliorate α-synuclein accumulation and
toxicity.
Increased susceptibility to oxidative stress
As shown in the early stereotaxic models of SND, neu-
rons in the striatum and SNc are uniquely susceptible to
oxidative stress induced by the mitochondrial toxins 3-
NP and MPTP, respectively [78]. The link between oxi-
dative stress and pathogenesis of both PD and MSA has
been explored in many experimental and epidemio-
logical studies. The animal and cell models of MSA
described above have yielded particularly intriguing
results regarding susceptibility to and impacts of oxidative
stress in oligodendrocytes overexpressing α-synuclein.
In animal models of MSA, intoxication with 3-NP has
the effect of enhancing the phenotype of MBP-hα-syn
and PLP-hα-syn mice to more closely resemble human
disease. In the PLP-hα-syn mouse, known for a relatively
benign motor and neurodegenerative phenotype, 3-NP
treatment caused a significant deterioration in motor be-
havior, which was greater than that in non-transgenic
mice undergoing the same regimen of intoxication.
Histopathologically 3-NP produced neurodegeneration
in typical MSA regions; the cerebellum, pons and infer-
ior olive. 3-NP did not appear to augment α-synuclein
pathology in transgenic or control mice. Intoxication of
MBP-hα-syn mice with 3-NP [79] intensified neuropath-
ology and motor deficits compared to vehicle treated
transgenic mice and 3-NP and vehicle treated non-
transgenic mice. In terms of regional selectivity, 3-NP
administration appeared to exacerbate neuronal and
oligodendrocyte pathology in most regions associated
with MSA, including the SNc and striatum. However,
oligodendrocyte loss in cerebellar white matter was not
significantly exacerbated by 3-NP. These results are con-
sistent with an increased vulnerability of α-synuclein
overexpressing oligodendrocytes to oxidative stress and
a regional selectivity of this effect that corresponds to
the distribution of MSA-P pathology.
3-NP intoxication of MBP-hα-syn mice also resulted in
biochemical changes resembling those reported in human
disease [79]. These included post-translational modifica-
tions of α-synuclein, with greater expression of nitrated α-
synuclein detected in oligodendrocytes of 3-NP treated
MBP-hα-syn mice compared to other groups. Analysis of
fractions of α-synuclein from brain homogenates ex-
tracted with different detergents revealed greater quantity
of oxidated and nitrated α-synuclein in less soluble frac-
tions of transgenic mice brains treated with 3-NP. Con-
versely, in the more soluble fraction, 3-NP treatment
reduced nitrated α-synuclein in MBP-hα-syn mice brain
compared to vehicle treated MBP-hα-syn mice. This sug-
gests that oxidative stress and resulting post-translational
modifications of α-synuclein may play a role in the solu-
bility shifts noted in MSA brain tissue [37].
Proteolytic dysfunction
As a major pathway for intracellular protein degradation,
the ubiquitin-proteasomal system has been a focus of
interest in neurodegenerative conditions featuring pro-
tein misfolding and aggregation. Decreased proteasomal
activity and/or down-regulation of proteasomal subunits
has been observed in several such conditions including
Alzheimer’s disease [80], DLB [81], PD [82], progressive
supranuclear palsy and MSA [83].
In the PLP-hα-syn model of MSA induction of proteo-
lytic stress by systemic proteasomal inhibition (PSI) re-
sulted in a remarkable exacerbation of the motor and
neurodegenerative phenotype closely resembling human
disease [84]. Most notably PSI treatment resulted in sig-
nificant neurodegeneration in the SNc, striatum, cerebel-
lar cortex (Purkinje fibres), inferior olive and pontine
nuclei but not regions typically spared by MSA, the
nucleus accumbens and deep cerebellar nuclei [84]. The
same regimen of PSI treatment had no discernible effect
on non-transgenic mice. Histopathologically, more se-
vere myelin pathology (thinning of myelin sheaths or
dilation and occupation with fibrillary material) and
oligodendrocyte degeneration were observed in affected
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regions of PSI treated PLP-hα-syn mice compared to
vehicle-treated littermates [84]. There was also an ap-
proximately 25 % increase in α-synuclein immunoreactiv-
ity in PSI-treated compared to vehicle treated transgenic
mice. Large fibrillar hα-syn inclusions were observed in
the myelin sheath after PSI-treatment, which were rarely
seen in vehicle treated PLP-hα-syn mice [84].
Proteasomal stress was also found to cause MSA-like
pathology in a cell model featuring overexpression of α-
synuclein in OLN-93 oligodendrocytes without p25α
coexpression. Riedel and colleagues [85] found no fibril-
lary inclusions or cytotoxicity in OLN-93 cells co-
expressing α-synuclein and tau. However, treatment with
either hydrogen peroxide (oxidative stress) or the pro-
teasomal inhibitor MG-132 caused recruitment of tau to
α-synuclein-positive aggregates and the formation of fila-
mentous structures. Treatment with both stressors
caused a shift of α-synuclein to more insoluble forms,
mimicking the change in solubility seen in MSA
specimens.
The extent to which proteasomal inhibition enhances
MSA-like pathology in these models of oligodendrocyte
α-synuclein overexpression strongly suggests that pro-
teasomal dysfunction plays an important role in the
pathophysiology of MSA. Further insights into the
mechanism of proteasomal dysfunction may open the
way for therapeutic targets to ameliorate α-synuclein
cytotoxicity.
Loss of oligodendrocyte trophic support
Loss of trophic support from oligodendrocytes in MSA has
been postulated as the mechanism for neurodegeneration
secondary to the primary glial pathology [86–88]. Ubhi et
al. [89] investigated the differential expression of neuro-
trophic factors in MBP-hα-syn mice and non-transgenic
control oligodendrocytes. MBP-hα-syn mice were com-
pared with two lines overexpressing α-synuclein in neurons
(PDGFβ-hα-syn and mThy1-hα-syn), α-synuclein knock-
out mice and non-transgenic control oligodendrocytes.
Out of three putatively glial-derived neurotrophic factors,
glial-cell derived neurotrophic factor (GDNF), brain de-
rived neurotrophic factor (BDNF) and insulin like growth
factor 1 (IGF-1), only GDNF was specifically decreased in
the MBP-hα-syn mice. In situ hybridization revealed no
difference in GDNF mRNA suggesting that α-synuclein
overexpression exerts a post-translational effect on its ex-
pression. Immunoblot of two MSA-affected regions from a
small sample of MSA (n = 3) and non-neurodegenerative
control brains (n = 3) suggested that reduction in GDNF
expression is also a feature of human disease. The authors
proceeded to investigate the neuroprotective efficacy of
GDNF infusions in MBP-hα-syn mice, which is discussed
below with other experimental therapies. This study sug-
gests that the specific decline in this glial neurotrophic
factor as a result of GCI-like pathology may be responsible
for the neurodegeneration and clinical phenotype previ-
ously reported in the MBP-hα-syn mouse [59].
The CNP-hα-syn mouse has also proved a useful model
for investigating the pathway from primary oligodendro-
cyte pathology to neurodegeneration. As described above,
Yazawa and colleagues [62] observed a surprising accumu-
lation of endogenous mouse α-synuclein in neurons in
response to oligodendrocyte overexpression of the human
form of the protein in CNP-hα-syn mice. Nakayama and
colleagues [49] replicated this neuronal accumulation of
endogenous α-synuclein in primary oligodendrocyte/
neuron cultures derived from CNP-hα-syn mice. The
authors hypothesized that neuronal α-synuclein accumu-
lation depended on oligodendrocyte dysfunction caused
by CNP-hα-syn overexpression. They found that arresting
glial proliferation in these cultures by treatment with
cytosine-1-β-D-arabinofuranoside ameliorated the neur-
onal α-synuclein accumulation. Furthermore treatment of
wild type oligodendrocyte/neuron cultures with condi-
tioned media from CNP-hα-syn cells resulted in accumu-
lation of endogenous α-synuclein in the previously
unaffected non-transgenic cells. These results suggest that
pathological signals from degenerating oligodendrocytes
transmitted to myelinated axons and into the extra-
cellular environment may alter neuronal α-synuclein
expression and contribute to neurodegeneration.
Prion-like transmission of α-synuclein
Although the above investigations lend support to the
categorization of MSA as a primary oligodendrogliopa-
thy with secondary neurodegeneration, a number of in-
vestigators have studied the potential role of neuron to
glia transmission of α-synuclein in animal and cell
models. The prion-like transmission of α-synuclein has
long been of interest as both a mode of propagation of
pathology in PD and as an explanation for the accumu-
lation of this predominantly neuronal protein in oligo-
dendrocytes in MSA. α-Synuclein exocytosis from
neurons has been well documented [90, 91] and various
forms of the protein can be found in cerebrospinal fluid
suggesting a certain amount of physiological secretion
[92, 93]. Uptake of extracellular α-synuclein by neurons
has also been documented resulting in aggregate forma-
tion and cell death in some studies [94–96]. In vivo, the
transmission of α-synuclein from neuron to neuron is
suggested by appearance of α-synuclein pathology in tis-
sue grafts (containing dopaminergic neuroblasts) in PD
brains many years after transplantation [97, 98]. Uptake
by other cell types, astrocytes and microglia, has been
documented both from a culture medium and the secre-
tion of neurons in co-culture, causing an inflammatory
response in the case of astrocytes [95, 99].
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More recent studies have shown that oligodendrocytes
also take up monomer and oligomer forms of α-synuclein
into their cytosol [100–102], apparently via dynamin-
depednent endocytosis [101, 102]. In KG1C oligodendro-
cytes, the recombinant α-synuclein taken up by the cells
formed aggregates of varying size, including some larger
perinuclear inclusions [101]. These had several features of
authentic GCIs including thioflavin S staining indicative of
fibrillar structure, ubiquitination, phosphorylation at S129
and colocalization with p25α. Uptake of α-synuclein was
also observed when KG1C cells were cultured with SH-
SY5Y neurons overexpressing α-synuclein. Reyes and
colleagues [102] injected fluorescent-labeled α-synuclein
into the neocortex of mice. Slices examined only 1 hour
after injection showed monomer and oligomer forms of α-
synuclein had entered oligodendrocytes around the injec-
tion site and were present in a diffuse or punctate pattern
throughout the cytoplasm. In another study, Watts and
colleagues injected brain homogenates of MSA patients
into the brains of mice that had no propensity to develop
neurological disease [103]. Inoculation with MSA homog-
enates induced a rapidly progressive neurological disease
characterized histologically by widespread neuronal α-
synuclein deposition; however, uptake by oligodendrocytes
in particular was not reported. Mice inoculated with hom-
ogenate from age matched non-neurodegenerative brains
showed no such changes. In a follow-up study Prusiner
and colleagues demonstrated that brain extracts from 14
MSA cases all transmitted neurodegeneration to mice
with development of neuronal α-synuclein deposition
[104]. In contrast, brain extracts from PD and control
cases did not induce aggregation of α-synuclein, suggest-
ing that the strain of α-synuclein found in MSA brain is
different to that of PD brain [104].
Cases of neuron to oligodendrocyte α-synuclein trans-
mission in vivo have also been reported. Reyes and col-
leagues [102] examined mice that had been injected with a
viral vector encoding human α-synuclein [105]. Three
weeks later embryonic rat tissue from the ventral mesen-
cephalon was transplanted into the region of the transduc-
tion. The authors found that in addition to α-synuclein
transmission to neurons in the grafted tissue, oligodendro-
cyte precursor cells and mature oligodendrocytes present
in the transplant also demonstrated human α-synuclein
immunopositivity. Studies in a double transgenic mouse
model (oligodendrocyte MBP-hα-syn and neuron PDGF-
hα-syn) demonstrated that α-synuclein accumulation
redistributed in oligodendrocytes comparable to the single
transgenic MBP-hα-syn model [106]. The authors provided
three possible causes for this phenomenon – redistribution
of α-synuclein from neurons to oligodendrocytes; sup-
pression of neuronal expression by unknown signals
from oligodendrocytes; and neuronal clearance of α-
synuclein.
Thus the prion-like hypothesis of α-synuclein trans-
mission in MSA has gained some support from both in
vitro and in vivo studies. These models of oligodendro-
cyte α-synuclein accumulation dispense with the need
for transcriptional upregulation of the protein and are
thus more consistent with the current evidence from hu-
man studies of MSA brain tissue [107–109]. However
while potentially more valid on the basis of known
pathogenesis, none of these models have so far achieved
the phenotypic resemblance to true MSA described in
the main transgenic animal models.
Exploring therapies for MSA
Animal and cell models provide essential platforms for
preclinical trials of prospective neuroprotective and dis-
ease modifying therapies in MSA.
Anti-inflammatory therapy
Astrogliosis and microglial activation are prominent
neuropathological findings in many of the animal models
described above [55, 59, 62, 110]. Stefanova and col-
leagues [110] observed that microglial activation and
toll-like receptor 4 (TLR4) expression was positively cor-
related with neurodegeneration in the PLP-hα-syn
mouse (Fig. 2). They proceeded to investigate the effect
of treatment with minocycline, a microglial activation in-
hibitor, in PLP-hα-syn mice from 2 to 4 months of age
(before the earliest observed onset of neuronal loss in
the SNc). Early minocycline treatment resulted in a sig-
nificant reduction in iNOS and TLR4 expression and
ameliorated neuronal loss in the SNc compared to
vehicle-treated transgenic mice.
Similarly myeloperoxidase (MPO) has been targeted
due to its role in immune cell-mediated oxidative dam-
age in MSA and other neurodegenerative diseases.
Treatment of 6-month old PLP-hα-syn mice intoxicated
by 3-NP with an MPO inhibitor (MPO-I) resulted in a
dose dependent improvement in motor deficits and pro-
tection of neurons in the striatum and SNc [111]. These
results were accompanied by reduced markers of inflam-
mation in the affected regions of MPO-I treated mice
compared to vehicle treated control oligodendrocytes.
Interestingly the authors also showed a reduction of
GCI-like pathology in MPO-I treated mice and reduced
prominence of the nitrated α-synuclein species previ-
ously noted in this animal model [79]. These results sug-
gest that inflammation plays an important role in
neurodegeneration in MSA (Fig. 2) and may even have a
more fundamental influence on α-synuclein modification
and GCI formation. However, these studies also show
that early intervention with anti-inflammatory agents,
preferably before onset of overt neuropathology, is ne-
cessary to achieve significant neuroprotection [110, 112].
This may limit the utility of such therapies in human
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disease where neuropathology is almost always well
established by the time of diagnosis. Nonetheless, further
investigation of anti-neuroinflammatory therapies in
MSA is certainly warranted.
Neurotrophic factor augmentation
Rasagiline is an inhibitor of monoamine oxidase type B
(MAOB) whose use as a symptomatic treatment in PD is
well established [113, 114]. In vitro studies have also sug-
gested a neuroprotective effect in PD models, though
human trials have been less convincing [115]. The neuro-
protective potential of rasagiline has been linked to induc-
tion of GDNF [116, 117], an oligodendrocyte-derived factor
that was selectively reduced in the brains of MBP-hα-syn
mice as described above [89]. Infusion of GDNF itself has
been proposed as a potential neuroprotective therapy and
was found to ameliorate clinical deficits and dendritic path-
ology (loss of MAP2 immunoreactive neruopil) in MBP-
hα-syn mice [89]. Thus, if its purported mechanism is legit-
imate, rasagiline may offer a less invasive alternative for
augmentation of GDNF in MSA brains. In the PLP-hα-syn
mouse model augmented with 3-NP intoxication, Stefanova
and colleagues [118] tested the neuroprotective efficacy of
low (0.8 mg/kg daily) and high-dose (2.5 mg/kg) rasagiline
in mice aged over 6 months. High does rasagiline (compar-
able to a reportedly tolerable human dose of 12 mg/day)
was associated with improvement in motor performance
indicators compared to control treated transgenic mice. On
neuropathological examination, high dose rasagiline miti-
gated neuronal loss in the striatum, cerebellar cortex, infer-
ior olive, SNc and pontine nuclei. This improvement was
dramatic in the SNc and pontine nuclei with neuron levels
comparable to healthy controls despite 30-60 % oligo-
dendrocyte loss in saline-treated transgenic mice.
Mesenchymal stem cells
The use of tissue grafts has long been of interest in neu-
rodegenerative diseases, particularly those with relatively
focal lesions such as PD. Early stereotaxic models of
MSA were frequently used to evaluate the efficacy of
grafting neural tissue into toxin-ablated basal ganglia.
More recently, however, the use of mesenchymal stem
cells (MSC) has presented itself as a relatively less inva-
sive and autologous procedure for regenerating damaged
neural pathways. Park and colleagues [119] found that a
single dose of human mesenchymal stem cells amelio-
rated neuron loss and motor deficit in a double-toxin
mouse model comprising concurrent administration of
MPTP and 3-NP to induce nigral and striatal degen-
eration respectively. Rescue of neurons in these re-
gions correlated with significantly reduced astro- and
micro-gliosis compared with saline treated intoxicated
animals, suggesting a possible immunomodulatory
effect of the MSC.
The effect of MSC infusion has also been tested in the
transgenic PLP-hα-syn mice [120]. PLP-hα-syn mice
aged 18 months (n = 12) were infused with mouse MSC.
Treatment did not appear to be associated with im-
provements in motor behavior compared to saline
treated transgenic mice (n = 6). However no healthy
non-transgenic controls were tested to assess the extent
of the baseline functional deficit in the PLP-hα-syn mice,
which has been noted to have a relatively subtle motor
phenotype. Nonetheless there did appear to be a modest
but significant recovery of dopamine neurons in the SNc
of the MSC group 4 weeks post treatment. α-Synuclein
levels in midbrain-brainstem lysates were not altered
between the two groups. A range of inflammatory cyto-
kines in these lysates was also tested and a significant
down regulation was observed for IL1α, IL-2, IL-10, IL-
17, GM-CSF, TGF-β1 and TNF-α. The reduction of
some of these cytokines was significantly correlated to
extent of neuronal rescue in the MSC-treated mice.
Although human MSC in the double toxin study were
identified histologically in the brains of treated mice, the
survival and fate of the transplanted cells in the trans-
genic mice was less certain. It will be difficult to deter-
mine whether the mechanism by which transplanted
MSC provide benefit is through in vivo differentiation to
replace damaged cells or via indirect immunomodula-
tory and trophic effects [121, 122].
Erythropoietin
Erythropoietin has been found to play a role in neuro-
protection and repair after ischaemic and hypoxic injury
in the brain [123, 124]. In vitro, erythropoietin promotes
differentiation and survival of dopamine neurons in
environments with differing oxygen tension [125]. A
neuroprotective effect was also found in vivo with pro-
tection against MTPT toxicity in mice [126] and survival
of dopamine neurons in mesencephalic grafts in a rodent
model of PD [127]. Building on this evidence, Kollen-
sperger and colleagues [128] examined the disease modi-
fying potential of peripherally delivered erythropoietin in
the PLP-hα-synuclein mouse model augmented with
chronic 3-NP intoxication. PLP-hα-syn animals intoxi-
cated with 3-NP were treated with either saline, early
erythropoietin (before intoxication) or late erythropoi-
etin (after intoxication). Unintoxicated transgenic mice
treated with erythropoietin were used as control. The re-
sults demonstrated a protective effect of erythropoietin
in both behavioral tests and neuronal loss in both the
SNc and the striatum. The study suggests erythropoietin
mitigates the enhanced toxicity of 3-NP usually observed
in this model of oligodendrocyte α-synuclein overexpres-
sion. The specificity of protection against 3-NP toxicity
in this model could not be determined due to the lack of
a non-erythropoietin non-intoxicated control group. The
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prominent non-neurological actions of erythropoietin,
particularly in hematopoiesis, make it an uncertain pro-
spect for long-term trials in humans.
Targeting GCI formation
Finally, models of MSA that recapitulate α-synuclein ag-
gregation and toxicity provide a platform for testing
therapies that aim to interrupt or reverse this key patho-
genic event. In the α-synuclein/p25α expressing OLN-93
model, Kragh and colleagues [48] tested three different
inhibitors of α-synuclein aggregation (Congo Red,
ASI1D peptide, and baicalein). All these agents signifi-
cantly attenuated the microtubule retraction and apop-
totic protein activation seen in untreated cells.
As noted above both rifampicin (a putative inhibitor of
α-synuclein self-association) and nocodazole (micro-
tubule depolymerizing agent) have been tested in pri-
mary cultures of oligodendrocytes and neurons from
CNP-hα-syn mice. Daily intraperitoneal rifampicin injec-
tions also showed promising results in MBP-hα-syn mice
(average 12 month old) [129]. Rifampicin treatment
significantly reduced α-synuclein aggregates, loss of den-
dritic complexity, neuronal loss and astrogliosis com-
pared to saline treated transgenic mice. Dendritic
complexity (MAP2 immunoreactivity) and neuronal cell
counts in rifampicin treated MBP-hα-syn mice were
comparable to healthy vehicle-treated non-transgenic con-
trol oligodendrocytes. A recent double-blinded placebo-
controlled trial of rifampicin in 100 MSA patients over
12 months did not show any effect on disease progression
as measured by a clinical rating scale [130]. Despite some
evidence of anti-aggregating properties in vitro, nocoda-
zole is not a strong candidate for animal and human trials
due to its unacceptable side effect profile.
Limitations of current models and future directions
Validity of α-synuclein overexpression
Despite the success of these models in replicating features
of the disease downstream of α-synuclein aggregation, it
remains a difficult task to reconcile this simulated mech-
anism with evidence from extensive studies of MSA brain
tissue. For one, demonstration of α-synuclein upregulation
at the transcriptional level has been stubbornly allusive in
human postmortem studies [107–109]. Indeed, the level
of physiological α-synuclein expression in oligodendro-
cytes is questionable with only a few studies demonstrat-
ing expression in this cell population under normal
conditions [131–133]. In contrast, duplication and tripli-
cation of the SNCA locus has been associated with both
familial and sporadic forms of PD [134–136]. Three point
mutations of the SNCA locus are also associated with
familial PD. Thus the status of α-synuclein as the likely
causative pathogenic molecule in PD does not necessarily
hold true in MSA. Nonetheless, primary or secondary
upregulation of α-synuclein in oligodendrocytes may yet
be implicated in MSA as there is scope for more sensitive
and cell-specific assays of oligodendrocyte expression
patterns in MSA specimens.
Distribution of pathology
The classical distribution of glial and neuronal degener-
ation in human disease has been the most difficult aspect
to replicate in the three basic murine models of MSA. Ini-
tial studies of the PLP-hα-syn mouse found no obvious
neurodegeneration [41], while later studies suggested GCI
formation and neural loss predominating in the basal gan-
glia, particularly the SNc [54, 55]. CNP-hα-syn mice dem-
onstrated most significant pathology in the spinal cord,
while MBP-hα-syn mice showed the most classical distri-
bution with both the basal ganglia and cerebellum severely
affected. The reasons for these regional disparities between
mouse lines sharing the same basic defect are obscure.
When Shults and colleagues [59] generated distinct MBP-
hα-syn lines with differing levels of α-synuclein expression,
there was a dramatic clinical and neuropathological
spectrum between the lowest and highest expressing lines.
Thus the disparate neurodegenerative phenotypes between
transgenic lines could result from different efficiencies of
the promoters expressing α-synuclein. However, the par-
ticular disparities in distribution of pathology may also sug-
gest that the three promoters target different subtypes of
oligodendrocytes.
The disparities in regional distribution of pathology in
MSA mouse models may shed light on the existence of
the subtypes MSA-C and MSA-P in human disease. The
transgenic mouse lines described above do not reproduce
the specific predominance of SND or olivopontocerebellar
atrophy. However, investigation of factors that modulate
the regional specificity of α-synuclein-mediated pathology,
such as 3-NP intoxication and proteasomal inhibition,
could shed light on the mechanism underlying the differ-
ent phenotypes.
To this end, more accurate characterization of the
three transgenic mouse lines is required. In particular, a
quantitative investigation of regional differences in the
level of oligodendrocyte α-synuclein expression and the
extent of GCI formation and neurodegeneration is re-
quired. It is important that control regions not typically
associated with MSA be included in these assays to test
the specificity of neuropathology in each models. A quan-
titative comparison of α-synuclein expression levels be-
tween models may determine whether the extent and
distribution of neuropathology is correlated with different
efficiency of the three promoters.
Induced pluripotent stem cells
While the cell models described above have proved use-
ful in furthering understanding of MSA pathology, there
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are a number of disadvantages to the common cell lines
in use. As described above, common permanent oligo-
dendrocyte cell lines have undergone some manner of
genetic modification to drive immortal cell growth and
may carry other artifacts to tissue culture [137]. While
the use of primary human cells would mitigate these pit-
falls, they are understandably difficult to obtain and do
not propagate well in culture. Pluripotent stem cells
such as those obtained from early embryos are able to
proliferate in vitro and differentiate into almost any ma-
ture cell type. Somatic cells isolated from adult patients
(in most cases from skin or bone marrow biopsies) can
be reprogrammed into a pluripotent state by overex-
pressing four transcription factors (Oct4, Sox2, Klf4 and
c-Myc) [138]. The resulting cells are termed induced
pluripotent stem cells (iPSCs) (Fig. 3). iPSCs can thus be
derived from patients with specific genetic or sporadic
diseases. Patient-specific iPSCs are then differentiated to
the key cell types that are affected in the disease in
question.
Pluripotent stem cells have been successfully derived
from patients with neurodegenerative diseases and have
yielded insights into pathophysiology and therapeutic
approaches. The first human iPSCs shown to model the
specific pathology seen in a genetically inherited disease
were derived from a child with spinal muscular atrophy
[139]. iPSC derived from four patients with Machado-
Joseph disease (Spinocerebellar ataxia type 3) were dif-
ferentiated into neurons and displayed a phenotype of
insoluble protein aggregate formation [140]. The authors
used these cells to demonstrate the key proteolysis of
ataxin 3 that precipitated aggregate formation. Differen-
tiation of the same iPSCs into glia allowed the authors
to show the specific vulnerability of neurons to the
disease process.
Recently, iPSCs were successfully derived from PD
[141–143] and MSA [144] patients and were differenti-
ated into neurons and oligodendrocytes respectively. As
a disease whose etiology is almost certainly multi-
factorial, MSA-derived iPSCs are likely to require add-
itional modifying factors to generate a phenotype (Fig. 3).
Factors that accelerate pathology such as oxidative stress
may still need to be used to manifest the disease pheno-
type. Nonetheless MSA-specific iPSC could be the key
to solving some of the enigmas surrounding this dis-
ease, including what precedes α-synuclein aggregation
in disease-affected oligodendrocytes, the role of tran-
scriptional upregulation of α-synuclein and the mech-
anism of neurodegeneration following oligodendrocyte
demise.
Conclusion
MSA is a devastating disease with extremely poor prog-
nosis. The cause of MSA is unknown and there is no
cure and current treatments are directed to addressing
only the symptoms. Recent studies utilizing animal
models that replicate the dynamics of α-synuclein aggre-
gation in oligodendrocytes and the subsequent neurode-
generation have made significant inroads in our
understanding of MSA pathogenesis. Such models have
been instrumental in determining the sequence of
pathogenic events in MSA brain, in particular the early
events leading up to GCI formation. They have helped
to identify molecular targets that could be exploited to
inhibit α-synuclein deposition in oligodendrocytes, pro-
viding potential therapeutic avenues for MSA therapy.
New developments in iPSC modeling will provide fur-
ther insights into the disease mechanisms underlying
this oligodendrogliopathy.
Fig. 3 Development of induced pluripotent stem cells (iPSCs) from MSA patients represents the most advanced in vitro modeling of MSA.
Somatic cells, such as skin fibroblasts, are reprogrammed into iPSCs using specific transcription factors. iPSCs are then differentiated into
oligodendrocytes that feature the key phenotype – glial cytoplasmic inclusion (GCI)
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